

**FACT SHEET**

# Large-scale antibody production: Hybridoma or recombinant?

After successful identification of a unique hybridoma for your therapeutic or diagnostic program, you need to quickly generate gram quantities for further evaluation. Here is the critical question:

What is the best production strategy?



**Large-scale hybridoma culture**



**Recombinant production**

## Comparison of key performance features

Features	Hybridoma	Transient TunaCHO <sup>SM</sup> platform
Expression level	10–50 mg/L	100–500 mg/L
Scale to reach 1 gram quantity	20–100 L	2–10 L
Cost	\$\$\$	\$
Timeline	4–6 months*	3–4 months**
Batch-to-batch consistency	Low	High
Security of long-term supply	Unstable	Stable
Pathway to GMP production	Difficult	Straightforward
Sequence verification	Not always. Lack of protection	Yes. Early patent protection

\*Hybridoma timeline estimates include cell line recovery, cell culture optimization, pilot production, and large-scale production.

\*\*Transient recombinant TunaCHO timeline estimates include hybridoma sequencing, gene synthesis and cloning, pilot production, and large-scale production.

***The choice is clear: go with Curia's TunaCHO<sup>SM</sup> transient production platform!***

To learn more, visit [curiaglobal.com/biologics](http://curiaglobal.com/biologics)

*Solutions developed by Curia*

**CONTACT US**

[www.curiglobal.com](http://www.curiglobal.com)